Aruna Biomedical Taps RiversEdge BioVentures for Strategic Advisory Services | GenomeWeb

NEW YORK (GenomeWeb News) - Stem cell research tools company Aruna Biomedical said yesterday that it has hired recently formed life sciences advisory and investment services firm RiversEdge BioVentures to evaluate strategic alternatives for Aruna.

RiversEdge will evaluate potential fundraising opportunities for Aruna, expansion of its strategic partnerships, and potential combinations with strategic and financial investors, among other services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.